Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.

Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R.

Clin Genitourin Cancer. 2019 Apr;17(2):e323-e328. doi: 10.1016/j.clgc.2018.12.009. Epub 2019 Jan 2.

PMID:
30686756
2.

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10.

Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu C, von Moos R.

J Geriatr Oncol. 2019 Mar;10(2):304-310. doi: 10.1016/j.jgo.2018.11.011. Epub 2018 Dec 14.

PMID:
30559073
3.

Awareness, attitudes, skills and training needs of psychiatrists working with adults with intellectual disability in managing epilepsy.

Lines G, Henley W, Winterhalder R, Shankar R.

Seizure. 2018 Dec;63:105-112. doi: 10.1016/j.seizure.2018.11.001. Epub 2018 Nov 14.

PMID:
30471519
4.

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

von Moos R, Koeberle D, Schacher S, Hayoz S, Winterhalder RC, Roth A, Bodoky G, Samaras P, Berger MD, Rauch D, Saletti P, Plasswilm L, Zwahlen D, Meier UR, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K; Swiss Group for Clinical Cancer Research (SAKK).

Eur J Cancer. 2018 Jan;89:82-89. doi: 10.1016/j.ejca.2017.11.005. Epub 2017 Dec 11.

PMID:
29241084
5.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.

6.

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).

Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei SB, Rauch D, Roggero E, Mohaupt MG, Bernhard J, Manetsch G, Gillessen S; Swiss Group for Clinical Cancer Research SAKK.

Prostate. 2016 Dec;76(16):1519-1527. doi: 10.1002/pros.23236. Epub 2016 Jul 25.

PMID:
27457964
7.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2016 Oct 10;16(1):780.

8.

Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: Long-Term Outcome.

Hess V, Winterhalder R, von Moos R, Widmer L, Stocker P, Jermann M, Herrmann R, Koeberle D.

Clin Colorectal Cancer. 2017 Sep;16(3):240-245. doi: 10.1016/j.clcc.2016.07.008. Epub 2016 Jul 30.

9.

Response to Pembrolizumab in a Patient with Relapsing Thymoma.

Zander T, Aebi S, Rast AC, Zander A, Winterhalder R, Brand C, Diebold J, Gautschi O.

J Thorac Oncol. 2016 Dec;11(12):e147-e149. doi: 10.1016/j.jtho.2016.07.018. Epub 2016 Aug 4. No abstract available.

10.

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S, Kühne R, Stenner F, Rothschild SI.

Clin Genitourin Cancer. 2017 Jun;15(3):e315-e323. doi: 10.1016/j.clgc.2016.06.011. Epub 2016 Jun 23.

PMID:
27450512
11.

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P.

Eur J Cancer. 2015 Jul;51(10):1212-20. doi: 10.1016/j.ejca.2015.03.016. Epub 2015 Apr 16.

PMID:
25892646
12.

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).

Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):167-72. doi: 10.1038/pcan.2015.8. Epub 2015 Mar 10.

PMID:
25753371
13.

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Frueh M, Kueng M, Popescu RA, Schacher S, Hess V, Herrmann R.

Ann Oncol. 2015 Apr;26(4):709-14. doi: 10.1093/annonc/mdv011. Epub 2015 Jan 20.

PMID:
25605741
14.

Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series.

Conen KL, Fischer N, Hofbauer GF, Shafaeddin-Schreve B, Winterhalder R, Rochlitz C, Zippelius A.

Dermatology. 2014;229(2):97-101. doi: 10.1159/000362384. Epub 2014 Jun 7.

15.

Pre-existing antihypertensive treatment predicts early increase in blood pressure during bevacizumab therapy: the prospective AVALUE cohort study.

Wicki A, Hermann F, Prêtre V, Winterhalder R, Kueng M, von Moos R, Rochlitz C, Herrmann R.

Oncol Res Treat. 2014;37(5):230-6. doi: 10.1159/000362376. Epub 2014 Apr 8.

PMID:
24853781
16.

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).

Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz SF, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder RC, Rochlitz C, von Moos R, Zaman K, Thürlimann BJ, Ruhstaller T; Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center.

Breast. 2014 Jun;23(3):244-9. doi: 10.1016/j.breast.2014.02.005. Epub 2014 Mar 20.

PMID:
24656636
17.

Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT.

Huellner MW, Collen TD, Gut P, Winterhalder R, Pauli C, Diebold J, Seifert B, Strobel K, Veit-Haibach P.

EJNMMI Res. 2014 Jan 22;4(1):6. doi: 10.1186/2191-219X-4-6.

18.

Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).

Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S.

Eur Urol. 2014 Sep;66(3):468-74. doi: 10.1016/j.eururo.2013.12.057. Epub 2014 Jan 4.

PMID:
24412228
19.

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; Swiss Group for Clinical Cancer Research (SAKK).

Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040. Epub 2013 Apr 6.

PMID:
23582881
20.

Multidisciplinary care in patients with prostate cancer: room for improvement.

Strebel RT, Sulser T, Schmid HP, Gillessen S, Fehr M, Huber U, Pless M, Morant R, Winterhalder R, Cathomas R.

Support Care Cancer. 2013 Aug;21(8):2327-33. doi: 10.1007/s00520-013-1791-x. Epub 2013 Mar 26.

PMID:
23529667
21.

Comparison of (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized Merkel cell carcinoma.

Epstude M, Tornquist K, Riklin C, di Lenardo F, Winterhalder R, Hug U, Strobel K.

Clin Nucl Med. 2013 Apr;38(4):283-4. doi: 10.1097/RLU.0b013e318281658e.

PMID:
23429397
22.

The clinical value of echocardiography and acoustic cardiography to monitor patients undergoing anthracycline chemotherapy.

Toggweiler S, Odermatt Y, Brauchlin A, Zander T, Müller A, Zuber M, Winterhalder R, Erne P.

Clin Cardiol. 2013 Apr;36(4):201-6. doi: 10.1002/clc.22074. Epub 2012 Nov 14.

23.

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.

Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, Burkhard R, Winterhalder R, Madlung A, Rauch D, Saletti P, Widmer L, Borner M, Baertschi D, Yan P, Benhattar J, Leibundgut EO, Bougel S, Koeberle D.

Ann Oncol. 2013 Mar;24(3):718-25. doi: 10.1093/annonc/mds519. Epub 2012 Nov 8.

24.

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK.

Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12.

25.

Antiangiogenic treatment for multiple CNS hemangioblastomas.

Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M.

Onkologie. 2012;35(7-8):443-5. doi: 10.1159/000341075. Epub 2012 Jul 3.

26.

Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer.

Huellner MW, Hennedige TP, Winterhalder R, Zander T, Venkatesh SK, Yong WP, Soo RA, Seifert B, Treumann TC, Strobel K, Veit-Haibach P.

Cancer Imaging. 2012 May 21;12:212-24. doi: 10.1102/1470-7330.2012.0021.

27.

Why do walk-in patients prefer a busy urban emergency department during office hours? A pilot survey of 200 consecutive patients from Switzerland.

Müller U, Winterhalder R, Businger A, Zimmermann H, Exadaktylos AK.

Swiss Med Wkly. 2012 May 31;142:w13565. doi: 10.4414/smw.2012.13565. eCollection 2012.

28.

Self-reported compliance with capecitabine: findings from a prospective cohort analysis.

Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Hermann F, von Moos R; SAEDA Investigators Group (Swiss prospective cohort group).

Oncology. 2011;80(1-2):29-33. doi: 10.1159/000328317. Epub 2011 May 23.

PMID:
21606661
29.

Epilepsy and intellectual disability: does epilepsy increase the likelihood of co-morbid psychopathology?

Arshad S, Winterhalder R, Underwood L, Kelesidi K, Chaplin E, Kravariti E, Anagnostopoulos D, Bouras N, McCarthy J, Tsakanikos E.

Res Dev Disabil. 2011 Jan-Feb;32(1):353-7. doi: 10.1016/j.ridd.2010.10.013. Epub 2010 Nov 16.

PMID:
21084171
30.

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).

Rochlitz C, Ruhstaller T, Lerch S, Spirig C, Huober J, Suter T, Bühlmann M, Fehr M, Schönenberger A, von Moos R, Winterhalder R, Rauch D, Müller A, Mannhart-Harms M, Herrmann R, Cliffe B, Mayer M, Zaman K; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2011 Jan;22(1):80-5. doi: 10.1093/annonc/mdq319. Epub 2010 Jul 1.

31.

Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.

Hess V, Pratsch S, Potthast S, Lee L, Winterhalder R, Widmer L, Cescato C, Lohri A, Jost L, Stillhart P, Pestalozzi B, Herrmann R.

Ann Oncol. 2010 Dec;21(12):2390-5. doi: 10.1093/annonc/mdq242. Epub 2010 May 5.

32.

Undifferentiated carcinoma of nasopharyngeal type (UCNT): a Swiss single-institutional experience during 1990-2005.

Sidler D, Thum P, Winterhalder R, Huber G, Haerle SK.

Swiss Med Wkly. 2010 May;140(19-20):273-9. doi: smw-12844.

33.

[Prostate cancer: a review of therapeutic strategies].

Winterhalder RC.

Praxis (Bern 1994). 2009 Oct 7;98(20):1149-53. doi: 10.1024/1661-8157.98.20.1149. Review. German.

PMID:
19809978
34.

Severe hyperkalemia and bilateral adrenal metastasis.

Nagler M, Müller B, Briner V, Winterhalder R.

J Oncol. 2009;2009:831979. doi: 10.1155/2009/831979. Epub 2010 Mar 2.

35.

[Medical emergencies in oncology: from case reports to recommendations].

Winterhalder RC, Müller B.

Praxis (Bern 1994). 2008 Apr 30;97(9):507-11. German.

PMID:
18557020
36.

Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.

Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M.

Br J Cancer. 2008 Apr 8;98(7):1204-9. doi: 10.1038/sj.bjc.6604297. Epub 2008 Mar 18.

37.

Gastric pneumatosis following polychemotherapy.

Zander T, Briner V, Buck F, Winterhalder R.

Eur J Intern Med. 2007 May;18(3):251-2.

PMID:
17449403
38.

Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.

Merrick DT, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith RL, Kennedy TC, Miller YE, Franklin WA, Hirsch FR.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2281-8.

39.
40.

Chemoprevention of lung cancer--from biology to clinical reality.

Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA Jr.

Ann Oncol. 2004 Feb;15(2):185-96. Review.

PMID:
14760107
41.

Glucagon-like peptide-1: a potent regulator of food intake in humans.

Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C.

Gut. 1999 Jan;44(1):81-6.

42.

Muscle lipofuscin content and satellite cell volume is increased after high altitude exposure in humans.

Martinelli M, Winterhalder R, Cerretelli P, Howald H, Hoppeler H.

Experientia. 1990 Jul 15;46(7):672-6.

PMID:
2373192

Supplemental Content

Loading ...
Support Center